|Application ||WB, IP|
|Calculated MW||86648 Da|
|Application & Usage||Western blotting (1:500 – 1:2500) and Immunoprecipitation. HeLa nuclear extract can be used as a positive control. However, the optimal concentrations should be determined individually. The antibody recognizes the BARD1 of human origin. Reactivity to other species has not been tested.|
|Other Names||BARD1, BARD-1|
|Formulation||100 µl affinity purified rabbit polyclonal antibody in phosphate-buffered saline (PBS) containing 30% glycerol, 1% BSA and 0.02% thimerosal.|
|Handling||The antibody solution should be gently mixed before use.|
|Reconstitution & Storage||-20 °C|
|Precautions||BARD1 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||E3 ubiquitin-protein ligase. The BRCA1-BARD1 heterodimer specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Plays a central role in the control of the cell cycle in response to DNA damage. Acts by mediating ubiquitin E3 ligase activity that is required for its tumor suppressor function. Also forms a heterodimer with CSTF1/CSTF-50 to modulate mRNA processing and RNAP II stability by inhibiting pre-mRNA 3' cleavage.|
|Cellular Location||Nucleus. Note=During S phase of the cell cycle, colocalizes with BRCA1 into discrete subnuclear foci. Can translocate to the cytoplasm. Localizes at sites of DNA damage at double-strand breaks (DSBs); recruitment to DNA damage sites is mediated by the BRCA1-A complex|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Mutations within the BRCA1 gene, localized to chromosome 17q, are believed to account for approximately 45% of families with increased incidence of both early-onset breast cancer and ovarian cancer. The BRCA1 gene is expressed in numerous tissues, including breast and ovary, and encodes a predicted protein of 1863 amino acids. This protein contains a RING domain near the N-terminus and appears to encode a tumor suppressor. BARD1 (BRCA1-associated RING domain protein 1) and BAP1 (BRCA1-associated protein 1) have both been shown to bind to the N-terminus of BRCA1 and are potential mediators of tumor suppression. BARD1 contains an N-terminal RING domain and three tandem ankyrin repeats. The C-terminus of BARD1 contains a region with sequence homology to BRCA1, termed the BRCT domain. BAP1 is a ubiquitin hydrolase and has been shown to enhance BRCA1-mediated cell growth suppression.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.